Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Grifols to buy Talecris for $3.4bn

Executive Summary

Plasma protein manufacturer Grifols SA will buy publicly traded Talecris Biotherapeutics Inc. (coagulation, immunology, critical care, neurology, and pulmonary treatments) in a deal valued at $3.4bn, plus $600mm in debt. Grifols is paying $19 in cash and issuing 0.641 new non-voting shares for each outstanding Talecris share. The implied price comes out to $26.16 per share (a 59% premium).
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Intra-Biotech Deal
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies